top of page

San Francisco CEO

January 10-11, 2026
Four Seasons, San Francisco 

Longwood Healthcare Leaders San Francisco CEO brings together leading biopharma CEOs, heads of R&D, top academic researchers, and life science investors the weekend prior to the JP Morgan Healthcare Conference for off-the-record discussion, held at the Four Seasons San Francisco. Join us for an intimate event with leaders in the industry.

SF CEO Header (2)_edited.png

2025 Featured Speakers

Academic & Regulatory Leaders
BioPharma CEOs
R&D and TA Heads
BD & Strategy Leaders
Investor Perspectives
San Francisco

Venue

San Francisco CEO is hosted in downtown San Francisco immediately prior to the JP Morgan Healthcare Conference.

Four Seasons Hotel San Francisco
757 Market Street
San Francisco, CA

415-633-3000

Four Seasons Terrace .jpeg

2025 Agenda

January 11, 2025

7:00 am

REGISTRATION & NETWORKING BREAKFAST

 

7:30 am

LONGWOOD FUND INTRODUCTION

Vikas Goyal, Venture Partner, Longwood Fund

​​​

8:00 am

BIG BIOPHARMA PIPELINE SOURCING

Peter BisgaardManaging Director, Pivotal Life Sciences

Bill MezzanotteGlobal Head, R&D, CSL

Paris Panayiotopoulos, Senior Managing Director, Blackstone Life Sciences

David Redfern, President, Corporate Development, GSK

Moderator: Vikas Goyal, Venture Partner, Longwood Fund

8:30 am

ADVANCING THE TRANSLATION OF BIOMEDICAL RESEARCH

Theresa Heah, CEO, Paratus Sciences

Don Ingber, Founding Director, Wyss Institute, Harvard University​

Anissa Kalinowski, CEO, Halo Biosciences

Bali Pulendran, Professor & Director, Institute for Immunity, Transplantation, & Infectious Disease, Stanford University

Moderator: Kara Carter, EIR, Evotec

9:00 am

FIRESIDE CHAT

Hal Barron, CEO, Altos Labs

Marc Tessier-LavigneCEO, Xaira
Moderator: Christoph Westphal, General Partner, Longwood Fund

9:20 am

DEVELOPING GLOBAL PARTNERSHIPS

Meeta Chatterjee, Chief Strategy Officer, Sun Pharma

Philippe Lopes-Fernandes, CBO, Ipsen

Thomas Mehrling, CEO, Helix BioPharma

Zhen Su, CEO, Marengo Therapeutics

Moderator: Daniel Palmacci, President, Cell & Gene, Lonza

 

9:55 am

NETWORKING BREAK

 

10:20 am

ACCELERATING DRUG DEVELOPMENT

Anirvan Ghosh, CEO, Unity Biotechnology

Carl Hansen, CEO, AbCellera

Shiva Malek, Global Head, Oncology, Novartis BioMedical Research

Phil Vickers, CEO, Solu Therapeutics

Moderator: Lisa Ricciardi, CEO, Cognition Therapeutics 

10:50 am

R&D COLLABORATION

Wolfram Carius, EVP, Cell & Gene Therapy, Bayer Pharmaceuticals

Ruxandra Draghia-Akli, EVP, Head, R&D, Novavax

Julie Gerberding, CEO, Foundation for the NIH 

Moderator: Ken Drazan, CEO, ArsenalBio

11:20 am

IMPACT & IMPORTANCE OF COMPANY CULTURE

Meg Alexander, President & COO, Ovid Therapeutics

Mathai Mammen, CEO, Parabilis Medicines

Ad Rawcliffe, CEO, Adaptimmune

Joanne Smith-Farrell, CEO, Be Bio

Moderator: Smita Pillai, SVP, Talent Development, Inclusion & Innovation Culture, Regeneron

11:50 am

FIRESIDE CHAT

Teresa Graham, CEO, Roche Pharma

Peter Marks, Director, CBER, FDA

Moderator: Kailash Swarna, Managing Director, Accenture

12:10 pm

NETWORKING LUNCHEON

 

1:00 pm

DRUG DISCOVERY SCIENCES

Dee Datta, CEO, Switch Therapeutics

JJ Kang, CEO, Appia Bio

Brent VaughanFounder, Stealth TechBio

Dominique Verhelle, CEO, NextRNA Therapeutics

Moderator: Raj Devraj, CEO, Rectify Pharmaceuticals

1:30 pm

ADVANCES IN CLINICAL TRIALS

Michael Amoroso, CEO, Precision BioSciences

Sandi Dunn, CEO, Phoenix Molecular Designs
Natalia Misciattelli, CEO, AAVantgarde Bio

Jim Wooldridge, CMO, Immunitas Therapeutics

Moderator: Greg Licholai, Chief Medical and Innovation Officer, ICON

 

2:00 pm

INNOVATIVE COMMERCIAL MODELS

Sabrina Johnson, CEO, Daré Biosciences

Matic Meglic, Global Executive Director, Industry Partnerships, Novartis

Kabir Nath, CEO, COMPASS Pathways 

Ram Palanki, CCO, REGENXBIO

Moderator: Steve Blaising, Chairman & Co-Founder, Brain Surgery Worldwide

2:30 pm

M&A AND DEAL-MAKING LANDSCAPE

Susan Hill, CEO, Mestag Therapeutics

Daphne KarydasPresident & CFO, Flare Therapeutics

Konstantina Katcheves, SVP, Innovative Medicines BD, Teva

Matthias Müllenbeck, SVP, Global Head, BD & Alliance Management, EMD Serono

Moderator: Jennifer Giottonini Cayer, CBO, Pulmocide

3:00 pm

NETWORKING BREAK

 

3:30 pm

REGULATORY ROUNDTABLE

Robert Califf, Commissioner, FDA

Steve Hahn, former Commissioner, FDA

Moderator: Christoph Westphal, General Partner, Longwood Fund

 

4:00 pm

RARE DISEASE INNOVATION

Peter Ghoroghchian, CEO, Latus Bio

Oscar Izeboud, CEO, Scenic Biotech

Shalini Sharp, Board Chair, Mahzi Therapeutics

Tamar Thompson, Head, Global Corporate Affairs, Alexion

Moderator: Preston Taylor, CFO, Greater Than One

 

4:30 pm

FINANCING INNOVATION

Lovisa Afzelius, General Partner, Flagship Pioneering 

Frank Nestle, Partner & CEO, Deerfield Discovery and Development

Vijay Pande, General Partner, a16z

Ursheet Parikh, Partner, Mayfield

Moderator: Omar Khalil, Managing Director, Investment Banking, Chardan

5:00 – 7:00 pm

COCKTAIL RECEPTION

January 12, 2025

7:00 am

REGISTRATION & NETWORKING BREAKFAST

 

7:30 am

LONGWOOD FUND INTRODUCTION

Aleks Radovic-MorenoPartner, Longwood Fund

8:00 am

DRIVING PRODUCTIVITY IN R&D

Nenad GrmusaCEO, DEM Bio

​Chris LooseCEO, Progentos

Kinnari PatelPresident, Head of R&D & COO, Rocket Pharmaceuticals

Richard Wilson, SVP, Primary Focus Lead, Astellas

​Moderator: Joel Schneider, CEO, Carbon Biosciences

8:30 am

POLICY IMPACT ON INNOVATION

Piraye BeimCEO, Celmatix Therapeutics

​Yigal Nochomovitz, Director, SMid Cap Biotech Analyst, Citi Research

Carissa RollinsCIO, Illumina

Joshua SharfsteinVice Dean & Professor, Health Policy & Management, Johns Hopkins

​Moderator: Courtney Silverthorn, VP, Strategic Alliances & Innovation, Foundation for the NIH

9:00 am

PLATFORM TO PIPELINE

Keith Gottesdiener, CEO, Prime Medicine

Larry Hamann, CEO, Interdict Bio

Sek Kathiresan, CEO, Verve Therapeutics

Daphne Koller, CEO, Insitro

Moderator: Harvey BergerCEO, Kojin Therapeutics

9:30 am

ALIGNING WITH REGULATORY AUTHORITIES

Judy Chou, CEO, AltruBio

Steve HahnCEO, Harbinger Health; former Commissioner, FDA

Thomas Lonngren, former Executive Director, EMA

Chrystal LouisCMO, TScan Therapeutics

Moderator: Shalabh Gupta, CEO, Unicycive Therapeutics

10:00 am

NETWORKING BREAK

 

10:20 am

FIRESIDE CHAT

​Levi Garraway, CMO, Roche Genentech

George YancopoulosPresident & CSO, Regeneron

​Moderator: Christoph Westphal, General Partner, Longwood Fund

10:40 am

PATIENT-CENTRIC DEVELOPMENT

Jessica BallingerCEO, Lyndra Therapeutics

Lyn Baranowski, CEO, Avalyn Pharma 

Lynn DurhamCEO, Stalicla

Amanda WagnerCEO, Immunitas

Moderator: Ariel Katz, CEO, H1

11:10 am

ACCESSING TECHNOLOGY TO ADVANCE THE PIPELINE

​Derek Adams, CEO, Stellular Bio

Mark Kotter, Founder, bit.bio 

Jonathan Powell, Head, Development, Calico Labs

Catherine Sabatos-Peyton, CEO, Larkspur Biosciences

Moderator: Uli Stilz, Founder & Head, Bio Innovation Hub, Novo Nordisk

11:40 am

BIG BIOPHARMA R&D

Johan LuthmanEVP, Head, R&D, Lundbeck

Bill Mezzanotte, Global Head, R&D, CSL

Tadaaki Taniguchi, CMO, Astellas

Moderator: Kailash Swarna, Managing Director, Accenture

12:10 pm

NETWORKING LUNCHEON

 

1:00 pm

FIRESIDE CHAT 

Jay BradnerEVP, R&D, & CSO, Amgen

Lloyd Minor, Dean, Stanford School of Medicine

Moderator: Christoph Westphal, General Partner, Longwood Fund

1:20 pm

EXTERNAL INNOVATION, IN-LICENSING AND SPIN-OUTS

Nouhad Husseini, SVP, Head, BD & Corporate Strategy, Regeneron

Vikram KarnaniCEO, Collegium Pharma

Bruce RogersPresident, Morphic Therapeutic

Beth ShaferCBO, Scholar Rock

Moderator: Navneet Kumar, CEO, Myra EB Systems

1:50 pm

UNITING THE BIOPHARMA INDUSTRY TO HELP PATIENTS

Grace Colon, CEO, Inaya Therapeutics

Will Lewis, CEO, Insmed

Ryan Richardson, Chief Strategy Officer, BioNTech

Catherine Sohn, Board Director, Altimmune

Moderator: Jeremy Levin, CEO, Ovid Therapeutics

2:20 pm

NETWORKING BREAK

 

2:50 pm

FIRESIDE CHAT

Stefan Oelrich, CEO, Bayer Pharmaceuticals

Robert Plenge, Chief Research Officer, BMS

Moderator: Christoph Westphal, General Partner, Longwood Fund

3:10 pm

THE NEXT WAVE OF TARGETED THERAPIES

Marianne De Backer, CEO, Vir Biotechnology

Maria FardisCEO, Lassen Therapeutics

Mat PletcherCSO, Weaver

Ioannis Sapountzis, Corporate SVP & Global Head, Therapeutic Areas, Boehringer Ingelheim

Moderator: John AlamCEO, CervoMed


3:40 pm

INVESTMENT OUTLOOK

Ann DeWitt, General Partner, Engine Ventures

Ansbert Gadicke, Managing Partner, MPM BioImpact

Rachel Mears, Partner, Jeito Capital

Rod WongManaging Partner, RTW Funds

Moderator: Aleks Radovic-MorenoPartner, Longwood Fund

Registration

Supporters

​To learn more about getting involved contact sg@longwoodfund.com

bottom of page